{'Year': '2008', 'Month': 'Jul'}
Lessons learned from development of docetaxel.
Docetaxel has benefited from focused evaluation of its preclinical pharmacology and pharmacokinetics, as well as the evolving areas that are becoming significant to cancer drug development: pharmacogenetics, population pharmacokinetics, and in vivo quantitative pharmacology.